Janux Therapeutics (NASDAQ:JANX) Stock Price Down 7.1% – Should You Sell?

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) fell 7.1% on Monday . The stock traded as low as $26.65 and last traded at $27.03. 208,899 shares changed hands during trading, a decline of 75% from the average session volume of 839,031 shares. The stock had previously closed at $29.10.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on JANX. William Blair reissued an “outperform” rating on shares of Janux Therapeutics in a report on Friday, January 10th. Leerink Partners raised their price target on Janux Therapeutics from $79.00 to $91.00 and gave the stock an “outperform” rating in a report on Tuesday, December 3rd. Wedbush reiterated an “outperform” rating and issued a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. Scotiabank dropped their price objective on Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating on the stock in a report on Friday, February 28th. Finally, Stifel Nicolaus lifted their target price on Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a report on Tuesday, December 3rd. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $92.44.

Janux Therapeutics Stock Performance

The stock has a market capitalization of $1.65 billion, a P/E ratio of -23.87 and a beta of 3.23. The firm has a 50-day moving average price of $35.05 and a 200 day moving average price of $45.71.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. On average, equities analysts anticipate that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Insider Transactions at Janux Therapeutics

In other Janux Therapeutics news, CEO David Alan Campbell sold 5,000 shares of the stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $60.00, for a total transaction of $300,000.00. Following the completion of the sale, the chief executive officer now owns 293,054 shares of the company’s stock, valued at $17,583,240. This represents a 1.68 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Andrew Hollman Meyer sold 13,334 shares of the business’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $54.88, for a total transaction of $731,769.92. Following the completion of the transaction, the insider now owns 82,139 shares in the company, valued at $4,507,788.32. The trade was a 13.97 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 25,002 shares of company stock worth $1,279,953. Company insiders own 29.40% of the company’s stock.

Institutional Trading of Janux Therapeutics

Several large investors have recently modified their holdings of JANX. Intech Investment Management LLC purchased a new position in Janux Therapeutics during the 3rd quarter valued at $368,000. Charles Schwab Investment Management Inc. boosted its stake in shares of Janux Therapeutics by 202.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock valued at $10,639,000 after purchasing an additional 156,675 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Janux Therapeutics by 27.2% during the third quarter. The Manufacturers Life Insurance Company now owns 30,595 shares of the company’s stock valued at $1,390,000 after buying an additional 6,547 shares during the period. Janus Henderson Group PLC raised its stake in Janux Therapeutics by 40.0% in the third quarter. Janus Henderson Group PLC now owns 2,523,406 shares of the company’s stock worth $114,587,000 after buying an additional 721,563 shares in the last quarter. Finally, Polar Asset Management Partners Inc. purchased a new stake in Janux Therapeutics in the third quarter worth about $613,000. 75.39% of the stock is owned by institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.